In this issue of Cancer Discovery, Fong and colleagues describe the encouraging observations of tumor regression, disease control, and survival of patients with otherwise refractory renal cell cancer with progressive disease after treatment with the conceptually novel oral antagonist of the A2A adenosine receptor (A2AR), ciforadenant. A2AR antagonists may represent the until now missing but critically important part of more effective immunotherapies of cancer, because they prevent the inhibition of tumor-reactive T and natural killer cells by blocking the immunosuppressive hypoxia-A2A-adenosinergic signaling, which represents an emerging immunosuppressive hallmark of tumors that are the most resistant to therapies.See related article by Fong et al., p. 40.

中文翻译：

---

A2A 腺苷受体拮抗剂使难治性肾细胞癌患者的肿瘤消退和存活的经验教训。

在本期《癌症发现》中，Fong 及其同事描述了在用概念上新颖的 A2A 腺苷受体 (A2AR) 口服拮抗剂治疗后出现进展性疾病的难治性肾细胞癌患者的肿瘤消退、疾病控制和存活率的令人鼓舞的观察结果，ciforadenant。A2AR 拮抗剂可能代表了迄今为止更有效的癌症免疫疗法中缺失但至关重要的部分，因为它们通过阻断免疫抑制性缺氧-A2A-腺苷能信号来阻止肿瘤反应性 T 细胞和自然杀伤细胞的抑制，这是一个新兴的免疫抑制标志对治疗最有抵抗力的肿瘤。参见 Fong 等人的相关文章，第 15 页。40.